- Trials with a EudraCT protocol (15)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
15 result(s) found for: School social work.
Displaying page 1 of 1.
| EudraCT Number: 2016-003052-70 | Sponsor Protocol Number: APAC2016 | Start Date*: 2016-11-10 | |||||||||||
| Sponsor Name:Academic Medical Center of Amsterdam | |||||||||||||
| Full Title: Initial non-operative treatment strategy versus appendectomy treatment strategy for simple appendicitis in children aged 7-17 years old. APAC study | |||||||||||||
| Medical condition: Acute uncomplicated (simple) appendicitis | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-002108-11 | Sponsor Protocol Number: SEP380-303 | Start Date*: 2022-02-10 | |||||||||||
| Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
| Full Title: A 12-Month Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Effectiveness of SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated ... | |||||||||||||
| Medical condition: Major Depressive Episodes Associated with Bipolar I Disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: BG (Prematurely Ended) SK (Prematurely Ended) HR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-000942-21 | Sponsor Protocol Number: AIMS-2-CT1 | Start Date*: 2019-07-24 | |||||||||||||||||||||
| Sponsor Name:Celso Arango | |||||||||||||||||||||||
| Full Title: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents w... | |||||||||||||||||||||||
| Medical condition: Autism Spectrum Disorder | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2015-004326-34 | Sponsor Protocol Number: MK8342B-060 | Start Date*: 2016-02-12 | ||||||||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | ||||||||||||||||||
| Full Title: A Phase 3 Randomized, Double-blind, Placebo-Controlled Trial to Study the Efficacy and Safety of MK-8342B (ENG-E2 vaginal ring) in Women with Moderate to Severe Primary Dysmenorrhea. | ||||||||||||||||||
| Medical condition: Moderate to severe primary dysmenorrhea | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Female | |||||||||||||||||
| Trial protocol: SE (Completed) PL (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2009-011235-12 | Sponsor Protocol Number: GT-21 | Start Date*: 2009-10-30 | |||||||||||
| Sponsor Name:ALK-Abelló A/S | |||||||||||||
| Full Title: GAP Grazax Asthma Prevention | |||||||||||||
| Medical condition: To prevent development of asthma - The aim of the trial is to investigate whether three consecutive years of treatment with Grazax (75.000 SQ-T) reduces the risk of developing asthma in children co... | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) DE (Completed) FI (Completed) DK (Completed) GB (Completed) SE (Completed) AT (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-005173-27 | Sponsor Protocol Number: 0858A4-318-WW | Start Date*: 2005-10-21 |
| Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development | ||
| Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF A COMBINATION OF LEVONORGESTREL AND ETHINYL ESTRADIOL IN A CONTINUOUS DAILY REGIMEN IN SUBJECTS WITH PREMENSTRUAL DYSPHORIC DISO... | ||
| Medical condition: Premenstrual dysphoric disorder (PMDD) affects 3% to 5% of menstruating women. PMDD is defined by markedly depressed mood, anxiety, and/or affective lability during the last week of the late lutea... | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: GB (Completed) FI (Completed) SE (Completed) DK (Completed) DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2007-003342-15 | Sponsor Protocol Number: F1D-MC-HGMT | Start Date*: 2007-12-05 |
| Sponsor Name:Eli Lilly and Company Limited | ||
| Full Title: A Randomized, Open-Label Study Comparing the Effectiveness of Olanzapine Pamoate Depot with Haloperidol Decanoate in the Treatment of Schizophrenia | ||
| Medical condition: Schizophrenia | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: HU (Prematurely Ended) FR (Completed) GB (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-000219-18 | Sponsor Protocol Number: PsiloRCT001 | Start Date*: 2018-04-09 | ||||||||||||||||
| Sponsor Name:Imperial College London | ||||||||||||||||||
| Full Title: Psilocybin vs. escitalopram for major depressive disorder: comparative mechanisms | ||||||||||||||||||
| Medical condition: Major Depressive Disorder | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2015-005282-22 | Sponsor Protocol Number: 42847922MDD2001 | Start Date*: 2017-10-24 | |||||||||||
| Sponsor Name:Janssen-Cilag International NV | |||||||||||||
| Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Adaptive Dose-Finding Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants... | |||||||||||||
| Medical condition: Major Depressive Disorder (MDD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) FI (Completed) BG (Completed) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-005625-11 | Sponsor Protocol Number: DC00050/91781 | Start Date*: 2009-09-08 | |||||||||||
| Sponsor Name:Bayer Healthcare AG | |||||||||||||
| Full Title: A multi-center, double-blind, double-dummy, randomized, controlled, parallel-group study to assess efficacy and safety of SH T00658ID compared to SH D593B in the treatment of primary dysmenorrhea | |||||||||||||
| Medical condition: Primary dysmenorrhea in women requesting oral contraception | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
| Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-001760-31 | Sponsor Protocol Number: J0022XST302 | Start Date*: 2013-07-04 | |||||||||||
| Sponsor Name:PIERRE FABRE MEDICAMENT | |||||||||||||
| Full Title: Clinical efficacy and safety of J022X ST in the prevention of Recurrent Upper-Respiratory Tract Infections (RURTI) in children with a high risk of recurrence | |||||||||||||
| Medical condition: Recurrent Upper-Respiratory Tract Infections (RURTI) | |||||||||||||
|
|||||||||||||
| Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) LT (Completed) PL (Completed) RO (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-004325-14 | Sponsor Protocol Number: MK8342B-059 | Start Date*: 2016-04-15 | ||||||||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc. | ||||||||||||||||||
| Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Study the Efficacy and Safety of MK-8342B (ENG-E2 Vaginal Ring) in Women with Moderate to Severe Primary Dysmenorrhea (with Optional ... | ||||||||||||||||||
| Medical condition: Treatment of primary dysmenorrhea | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Female | |||||||||||||||||
| Trial protocol: DE (Completed) FI (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2019-002704-41 | Sponsor Protocol Number: 18498A | Start Date*: 2020-03-13 | |||||||||||
| Sponsor Name:H. Lundbeck A/S | |||||||||||||
| Full Title: A randomised, double-blind, parallel-group, active controlled study evaluating the efficacy of vortioxetine versus desvenlafaxine in adult patients suffering from major depressive disorder with par... | |||||||||||||
| Medical condition: Major depressive disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) EE (Completed) LV (Completed) BG (Completed) SK (Completed) BE (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-023483-41 | Sponsor Protocol Number: I10E-0718 | Start Date*: 2011-03-01 | |||||||||||||||||||||
| Sponsor Name:LFB BIOTECHNOLOGIES | |||||||||||||||||||||||
| Full Title: A MULTICENTER STUDY ON THE EFFICACY, SAFETY AND PHARMACOKINETICS OF I10E IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY (PID) | |||||||||||||||||||||||
| Medical condition: a primary immunodeficiency as defined by the ESID and validated by a reference centre : • X-linked agammaglobulinemia (XLA) • Common variable immunodeficiency (CVID) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: HU (Completed) FR (Completed) Outside EU/EEA | |||||||||||||||||||||||
| Trial results: Removed from public view | |||||||||||||||||||||||
| EudraCT Number: 2009-017744-14 | Sponsor Protocol Number: RGB113905 | Start Date*: 2010-07-28 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
| Full Title: An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults with Partial-Onset Seizures. | |||||||||||||
| Medical condition: Epilepsy - partial-onset seizures with or without secondary generalisation | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) DE (Completed) ES (Completed) FR (Completed) BE (Completed) DK (Completed) IT (Completed) BG (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.